Affiliation:
1. Department of Cardiovascular Sciences, Catholic University of the Sacred Heart (UCSC) , Rome , Italy
2. Department of Diagnostic Imaging, area of Cardiovascular and Interventional Imaging, Abruzzo Health Unit 1 , L'Aquila , Italy
3. Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome , Italy
Abstract
Abstract
Background
Cardiac amyloidosis (CA) is a rapidly progressive infiltrative cardiomyopathy, whose role is emerging as a not-so-rare disorder leading to heart failure (HF). Myocardial bridge (MB) is the most common inborn coronary artery variant, and its clinical relevance is still matter of debate. The exceptional coexistence of these two conditions could accelerate disease progression and worsen the already compromised clinical conditions.
Case summary
We present the case of a 76-year-old female patient experiencing relapsing HF decompensation and presenting to our centre with dyspnoea at rest and severe peripheral congestion. Echocardiogram showed severe concentric hypertrophy, severe biventricular contractile dysfunction, and third-degree diastolic dysfunction. Coronary angiography excluded epicardial atherosclerotic disease, though displaying a long intramyocardial course of left anterior descending artery. Physiological invasive test was achieved in terms of instantaneous wave-free ratio (iFR), both at baseline and after inotropic and chronotropic stimuli, and attested haemodynamic significance. Concurrently, the diagnostic flow chart for CA was accomplished, by means of both invasive (periumbilical fat biopsy, bone marrow aspiration) and non-invasive tests (99mTc-diphosphonate scintigraphy, serum-urine immunofixation) that confirmed the suspect of primary amyloidosis. Acute HF therapy was personalized according to the singularity of the case, avoiding both nitrates and beta-blockers, then first cycle of chemotherapy was started.
Discussion
Our clinical case shows a unique interaction between infiltrative cardiomyopathy and coronary artery abnormality. Amyloidosis can contribute to the ischaemic burden of the MB and this may, in turn, abbreviate the path to HF decompensation.
Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine
Reference19 articles.
1. Free light chains a novel biomarker of cardiovascular disease. A pilot study;Basile;Eur Rev Med Pharmacol Sci,2019
2. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy;Falk;J Am College Cardiol,2016
3. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases;Garcia-Pavia;Eur Heart J,2021
4. Myocardial bridging: an up-to-date review;Lee;J Invasive Cardiol,2015
5. “A bridge over troubled water”: a case report;D’amario;Eur Hear J Case Rep,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献